Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN)
On December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $768 from $767 and kept an Equal Weight rating.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 926,200 | $520,774,474 | -2% | 1.04% |
| 2. | D E Shaw D. E. Shaw | 861,593 | $484,447,896 | +11% | 0.27% |
| 3. | AQR Capital Management Cliff Asness | 721,354 | $405,595,821 | +529% | 0.26% |
| 4. | 400,000 | $224,908,000 | +793% | 2.15% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 386,884 | $217,533,266 | +62% | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $800.00 | 1,500 | $1,200,000.00 | 1,703 | 2026-01-07 | Filing | |
| $750.00 | 760 | $570,000.00 | 1,548 | 2025-11-20 | Filing | |
| $651.43 | 431 | $280,766.33 | 4,233 | 2025-11-07 | Filing | |
| $657.29 | 388 | $255,028.52 | 2,352 | 2025-10-29 | Filing | |
| $656.50 | 712 | $467,428.00 | 2,740 | 2025-10-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 233,231 | $180,024,012 | 0.25% | |
| 2. | 161,738 | $124,840,710 | 0.19% | |
| 3. | 137,321 | $105,809,950 | 0.09% | |
| 4. | 128,317 | $99,044,043 | 0.32% | |
| 5. | 67,300 | $51,946,851 | 4.78% |
News See All
10 Best Debt Free Dividend Stocks to Buy Now
Debt was once avoided by most S&P 500 technology companies. That mindset is changing.
Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating
On December 4, BMO Capital analyst Evan Seigerman boosted the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $850 from $725 and maintained an Outperform rating on the stock.
14 Best US Stocks to Buy for Long Term
Investors around the world focus on long-term strategies, and for that, they are looking beyond traditional investment ideas.
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on REGN.
Jim Cramer Answered Questions About These 7 Stocks
Jim Cramer, the host of Mad Money, said on Thursday that cryptocurrency-related stocks, especially those tied to Bitcoin, have been sliding, and he warned that it can possibly pull the tech sector down...
Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript October 28, 2025Regeneron Pharmaceuticals, Inc. beats earnings expectations.
Hedge Fund Resource Center Billionaire Hedge Funds
